PTGX / FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dines more_horizontal

Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, more_horizontal

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-afte more_horizontal

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectivene more_horizontal

The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares more_horizontal

Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing phase more_horizontal